These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 21353963)

  • 1. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE; Sader HS; Jones RN
    Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).
    Mendes RE; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):93-7. PubMed ID: 21851873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of dalbavancin against staphylococci isolated in Istanbul, Turkey.
    Aktas G; Derbentli S
    Chemotherapy; 2010; 56(6):444-7. PubMed ID: 21088395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
    Sader HS; Mendes RE; Duncan LR; Pfaller MA; Flamm RK
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC; Sader HS; Jones RN
    Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
    Farrell DJ; Krause KM; Benton BM
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):275-9. PubMed ID: 21353951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
    Mendes RE; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.
    Farrell DJ; Liverman LC; Biedenbach DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):415-20. PubMed ID: 21982563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
    Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
    Jansen WT; Verel A; Verhoef J; Milatovic D
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3420-4. PubMed ID: 17606689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S; Warner M; Johnson AP; Livermore DM
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
    Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M;
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.